Clinical trials
Alopecia Areata clinical trials
Below are recruiting alopecia areata clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07152119Recruiting
Study of Litfulo for severe alopecia areata in routine care
This study looks at how well Litfulo capsules work for people with severe alopecia areata in everyday medical practice. It is for adults and teens aged 12 or older who are starting Litfulo as part of their normal care.
SeoulAges 12 years+ - NCT05745389Recruiting
Alopecia areata registry to track treatment safety and results
This registry collects information from adults with alopecia areata who are starting or taking certain approved medications. It helps researchers understand how well these treatments work and how safe they are in real-world care.
Waltham, MassachusettsAges 18 years+ - NCT06562270Recruiting
Teens with severe alopecia areata: treatment safety study
This study tracks the safety and effectiveness of alopecia areata treatments in teenagers aged 12-17. It helps doctors understand which treatments work best and are safest for young people with severe hair loss.
Waltham, MassachusettsAges 12–17 - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT07242638RecruitingPhase 2
Abrocitinib for skin and hair loss in Down syndrome
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
New York, New YorkAges 12 years+ - NCT07136467Recruiting
Understanding daily life with vitiligo, alopecia areata, or hidradenitis suppurativa
This study looks at how certain skin conditions affect daily life in teens and adults. Researchers want to understand the challenges people face with vitiligo, alopecia areata, or hidradenitis suppurativa by having participants fill out simple questionnaires.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 12 years+ - NCT06801821Recruiting
Stigma study on skin conditions
This study looks at how people view those with certain skin conditions. It aims to understand stigma, which may help improve awareness and support.
Roma, ItaliaAges 18 years+ - NCT07554222RecruitingPhase 1
Safety study of IBI3013 for vitiligo and hair loss
This is an early-stage safety study of a new drug called IBI3013. The trial tests how safe the drug is and how your body processes it. It enrolls healthy volunteers first, then people with vitiligo (loss of skin color) or severe alopecia areata (patchy hair loss).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06573593Recruiting
JAK inhibitors for children with alopecia areata
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
Hangzhou, ZhejiangAges 2–80 - NCT07250997Recruiting
PALLAS laser study for skin conditions
This trial tests a new laser (PALLAS) that delivers targeted UVB light to treat skin conditions like psoriasis or eczema. It may help if your doctor thinks your skin problem could improve with UVB therapy.
Szeged, Csongrád-Csanád VármegyeAges 18–65 - NCT05928169Recruiting
Tracking how inflammatory skin conditions change over time
This study looks at what affects the “path” (trajectory) of long-lasting inflammatory skin conditions. It may help researchers understand why symptoms change and how treatments or factors influence those changes.
KielAges birth–80 years - NCT05551793RecruitingPhase 2
Dupilumab for patchy hair loss with scalp inflammation
This Phase 2 trial tests dupilumab (an injection medicine) to regrow hair in people with alopecia areata, a condition where the immune system attacks hair follicles. It may help by reducing the immune-related inflammation linked to hair loss.
Irvine, CaliforniaAges 18 years+
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alopecia areata?
- Yes. Clin2 currently lists 36 recruiting alopecia areata studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alopecia areata trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alopecia areata trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.